In 2018, Laubli et al. evaluated the serological responses to vaccination against Influenza A/H1N1, Influenza A/H3N2, and Influenza B/Brisbane at different time points after vaccine administration in cancer patients undergoing PD-1 blockade (either Nivolumab or Pembrolizumab) and healthy age-matched controls. This evidence concerns the gene PDCD1 and cancer.